Who Paid My Doc
Nicholas Borja
Clinical Genetics (M.D.) Miami, FL Medical Doctor
NPI 1982995015 CMS profile 7221466
1601 Nw 12Th Ave Fl 1, Miami, FL 33136
General payments
$41
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Nicholas Borja of Miami, FL is reported in the CMS Open Payments database as having received $41 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 14th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $24 | 1 | |
| 2021 | General | $17 | 1 |
Beside peers
- Nicholas Borja
- Clinical Genetics (M.D.) median
- Middle half of Clinical Genetics (M.D.)
- National median
In program year 2025, general payments to Nicholas Borja were reported at $0. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.
Show as a table
| Year | Nicholas Borja | Clinical Genetics (M.D.) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $130 | $24–$2,691 | $163 |
| 2020 | $0 | $126 | $30–$3,700 | $114 |
| 2021 | $17 | $185 | $30–$3,777 | $132 |
| 2022 | $0 | $136 | $44–$2,749 | $149 |
| 2023 | $0 | $196 | $55–$5,220 | $160 |
| 2024 | $24 | $165 | $46–$3,171 | $164 |
| 2025 | $0 | $255 | $85–$3,583 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$7,548
Medicare patients
42
Services billed
73
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 69% | |
| Cancer | 60% | |
| Arthritis | 60% | |
| Diabetes | 36% | |
| Ischemic heart disease | 31% | |
| Chronic kidney disease | 26% | |
| Depression | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Genetics (M.D.) in Florida
Roberto Zori
Clinical Genetics (M.D.) · Gainesville, FL
Amarilis Sanchez Valle
Clinical Genetics (M.D.) · Tampa, FL
Paldeep Atwal
Clinical Genetics (M.D.) · West Palm Beach, FL
Parul Jayakar
Clinical Genetics (M.D.) · Miami, FL
Deborah Barbouth
Clinical Genetics (M.D.) · Miami, FL
Ingrid Cristian
Clinical Genetics (M.D.) · Orlando, FL
Related records
Clinical Genetics (M.D.) in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Genetics (M.D.)
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.